Argenx Se - American Depositary Shares (ARGX) closed at $981.33 on November 12, 2026, up 0.4% from the previous close, on volume of 371,986 shares (30-day average 449,965).
Data as of November 12, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 23, 2026 | Calendar Put Ladder with Ratio | 20-Nov-26800[331x] : 820[221x] P|18-Dec-26840[331x] P | 883 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
Globe Newswire (Tue, 10-Nov 5:54 PM ET)
Analysts Are Bullish on Top Healthcare Stocks: Myomo (MYO), Maze Therapeutics, Inc. (MAZE)
TipRanks (Tue, 10-Nov 6:40 AM ET)
TipRanks (Tue, 10-Nov 6:30 AM ET)
Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Voyager Therapeutics (VYGR)
TipRanks (Tue, 10-Nov 2:50 AM ET)
arGEN X (0QW0) Gets a Buy from J.P. Morgan
TipRanks (Mon, 9-Nov 5:55 AM ET)
Globe Newswire (Mon, 9-Nov 1:00 AM ET)
Globe Newswire (Mon, 9-Nov 1:00 AM ET)
Globe Newswire (Sat, 7-Nov 10:01 AM ET)
argenx to Present at Upcoming Investor Conferences
Globe Newswire (Tue, 3-Nov 1:00 AM ET)
Market Chameleon (Thu, 22-Oct 5:17 AM ET)
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Argenx Se - American Depositary Shares trades on the NASDAQ stock market under the symbol ARGX.
As of November 12, 2026, ARGX stock price climbed to $981.33 with 371,986 million shares trading.
ARGX has a beta of 0.03, meaning it tends to be less sensitive to market movements. ARGX has a correlation of 0.00 to the broad based SPY ETF.
ARGX has a market cap of $61.71 billion. This is considered a Large Cap stock.
Last quarter Argenx Se - American Depositary Shares reported $2 billion in Revenue and $7.80 earnings per share. This beat revenue expectation by $112 million and exceeded earnings estimates by $28.58.
In the last 3 years, ARGX traded as high as $1,072.75 and as low as $327.73.
The top ETF exchange traded funds that ARGX belongs to (by Net Assets): IBB, CGGO, FBT, AVDE, BBH.
ARGX has underperformed the market in the last year with a return of +10.3%, while SPY returned +12.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ARGX shares. However, ARGX has outperformed the market in the last 3 month and 2 week periods, returning +13.5% and +10.0%, while SPY returned -1.5% and -2.0%, respectively. This indicates ARGX has been having a stronger performance recently.
ARGX support price is $954.18 and resistance is $1,000.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARGX shares will trade within this expected range on the day.
